1.Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results.
Sang Uk PARK ; Seung Jun LEE ; Moosang KIM
Korean Journal of Ophthalmology 2014;28(4):306-313
PURPOSE: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC). METHODS: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed. RESULTS: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012). CONCLUSIONS: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.
Acute Disease
;
Adult
;
Angiogenesis Inhibitors/*therapeutic use
;
Bevacizumab/therapeutic use
;
Central Serous Chorioretinopathy/*drug therapy/physiopathology
;
Female
;
Humans
;
Intravitreal Injections
;
Male
;
Middle Aged
;
Observation
;
Ranibizumab/therapeutic use
;
Retinal Photoreceptor Cell Inner Segment/pathology
;
Retinal Photoreceptor Cell Outer Segment/pathology
;
Retrospective Studies
;
Subretinal Fluid/drug effects
;
Tomography, Optical Coherence
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
2.Treatment of Serous Retinal Detachment Associated with Choroidal Ischemia with Intravitreal Bevacizumab Following Brain Surgery.
Young Joo CHO ; Eun Young CHOI ; Hyoung Jun KOH ; Sung Chul LEE ; Min KIM
Korean Journal of Ophthalmology 2014;28(5):424-426
No abstract available.
Angiogenesis Inhibitors/*therapeutic use
;
Bevacizumab/*therapeutic use
;
Choroid/*blood supply
;
Ciliary Arteries/pathology
;
Fluorescein Angiography
;
Humans
;
Intravitreal Injections
;
Ischemia/*drug therapy/etiology/physiopathology
;
Male
;
Meningeal Neoplasms/surgery
;
Meningioma/surgery
;
Neurosurgical Procedures/*adverse effects
;
Retinal Detachment/*drug therapy/etiology/physiopathology
;
Subretinal Fluid
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity/physiology
;
Young Adult
3.Time-Lag between Subretinal Fluid and Pigment Epithelial Detachment Reduction after Polypoidal Choroidal Vasculopathy Treatment.
Ju Byung CHAE ; Joo Yong LEE ; Sung Jae YANG ; June Gone KIM ; Young Hee YOON
Korean Journal of Ophthalmology 2011;25(2):98-104
PURPOSE: The goal of the present research was to study post-treatment changes in polypoidal choroidal vasculopathy (PCV) shown by optical coherence tomography (OCT). METHODS: The study included 12 patients with naive PCV. Photodynamic therapy and 3 consecutive intravitreal bevacizumab injections at 6-week intervals were given. Best corrected visual acuity, subretinal fluid (SRF), pigment epithelium detachment (PED), central macular thickness (CMT), and total macular volume (TMV) were measured before and after treatment as assessed by Stratus OCT3. RESULTS: After treatment, the SRF height decreased earlier than the PED height. The SRF diameter decreased with statistical significance. However, the PED diameter did not show a statistically significant improvement, persisting at pre-treatment levels. Both CMT and TMV decreased significantly after treatment. CONCLUSIONS: After PCV treatment, SRF and PED stabilized, as shown by OCT. However, the PED treatment response was both delayed and refractory compared to the SRF response. The small change in post-treatment PED diameter may suggest the possibility of PCV recurrence.
Aged
;
Choroid/*pathology
;
Choroid Diseases
;
Choroidal Neovascularization/diagnosis/*drug therapy
;
Disease Progression
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Male
;
Photochemotherapy/*adverse effects
;
Prognosis
;
Retinal Detachment/diagnosis/*etiology
;
Retinal Pigment Epithelium/*pathology
;
Retrospective Studies
;
*Subretinal Fluid
;
Time Factors
;
Tomography, Optical Coherence
;
Visual Acuity